Abstract
This study verifies the preclinical therapeutic effect of YM-1 silencing BAG3 combined with cetuximab targeted atepidermal growth factor receptor (EGFR) on Triple-Negative Breast Cancer (TNBC ) cell lines both in vitro and invivo. TNBC is defined as a unique subtype of breast cancer that leads to an increase in patients with interval cancerswhich can be detected annually. In actual research, targeted molecular therapies are involved in the field because of theimmunological heterogeneity of TNBC. YM-1 has a potentially better inhibition target for EGFR instead of BAG3. Byreviewing some existing preclinical research and targeted treatment for TNBC, this study is to propose a novel treatmenttarget for TNBC based on cetuximab treatment.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
